Birtamimab Under Investigation in Mayo Stage IV AL Amyloidosis

Morie A. Gertz, MD, discusses the limitations of the current Mayo Stage IV amyloidosis treatment landscape, the rationale for investigating birtamimab in this population, and the importance of raising awareness for the AFFIRM-AL trial.

Related Keywords

Minnesota ,United States ,Moriea Gertz ,Caelum Biosciences ,Mayo Clinic Comprehensive Cancer Center ,Mayo Stage ,Physical Component Summary ,General Internal Medicine ,D ,